Xu Yuan

This profile gathers the share dealings of Xu Yuan across 3 companies, led by IGG Inc, Fate Therapeutics Inc and Akero Therapeutics, Inc. Between 5 December 2017 and 28 May 2026, the trades on record add up to 47 filings.

Market trades split into 21 purchases (€209.5M) and 18 sales (€38.1M). No amount is published for 11 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 share grants. 2026 to date brings 6 purchases and 2 sales.

Half of the purchases are above €1.9M and half below. Scaled by market value, the purchases weigh a median 5.3% of market cap (sample: 4 purchases). On 6 out of 6 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 100% of cases, with a median move of +3.0%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 1 June 2026, the filings show a transaction in IGG Inc. The last insider purchase was made public on 1 June 2026, 145 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.